|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contributor Cindy H. Dubin reviews how the addition of electronic and connectivity to inhalers may improve patient adherence and, consequently, treatment efficacy.
|
|
|
Timothy J. Smith, RPh, PhD, reviews how derivatives of aurintricarboxylic acid (ATA), a commercial reagent for aluminum ion determination, are under consideration for drug development in view of ATA’s diverse pharmacological spectrum.
|
|
|
Andrew Leber, PhD, Raquel Hontecillas, PhD, and Josep Bassaganya-Riera, PhD, say current IBD therapeutics have mediocre efficacy, poor maintenance of response, and damaging side effects, including cancer, infection, and death, resulting in an unmet clinical need for safer and more effective oral therapeutics.
|
|
|
Roger Humphrey, MBA, says as companies pursue various and unique collaborative platforms, their real estate needs are changing — with profound implications for how and where life sciences companies choose to operate.
|
|
|
Jim Huang, PhD, says more than 50% of approved drugs on the market contain poorly water soluble APIs, which typically are associated with poor bioavailability, suboptimal drug delivery, ineffective drug efficacy, and side effects, and this creates a huge opportunity in generating 505(b)(2) products.
|
|
|
|
|
|
|
|
|

Frontage is a CRO providing integrated, scientifically driven research, analytical, and development services throughout the drug discovery and development process to enable biopharmaceutical companies to achieve their drug development goals. We offer our clients comprehensive services in analytical testing and formulation development, drug metabolism, and pharmacokinetics (DMPK), bioanalysis, preclinical safety and toxicology, and early phase clinical studies. We have enabled many innovator, generic and consumer health companies of all sizes to file IND, NDA, ANDA, BLA and 505(b)(2) submissions in global markets allowing for successful development of important therapies and products for patients. We successfully assist clients to advance hundreds of molecules through development to commercial launch in global markets. We are committed to providing rigorous scientific expertise to ensure the highest quality and compliance. Click here for more.
|
|
|
|
|
|
 |
|
Soligenix, Inc. recently announced today it has reached a significant milestone in the Phase 3 clinical study (the “DOM-INNATE” study) for SGX942 (dusquetide) in the treatment of oral mucositis in patients with head and neck cancer (HNC).
|
|
 |
|
Hovione Technology, a specialist in development of innovative inhalation device technology, recently announced it has secured global rights to develop and commercialize a new ultra-affordable, multi-use blister-based dry powder inhaler patented by inventor Dr. Klaus-Dieter Beller.
|
|
 |
|
Catalent, Inc. and Paragon Bioservices, Inc. and Catalent Inc. recently announced they have entered into a definitive agreement under which Catalent will acquire Paragon for $1.2 billion.
|
|
|
|
|
Upcoming eNewsletter Features:
May 1 – Formulation Development
May 8 – Prefilled Syringes
|
|
|
|
|
|
|
|